









Markets
/
Stocks
/
nasdaq-ctkb
/

Cytek Biosciences Inc

CTKB

4.620USD

+0.080+1.76%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

590.74MMarket Cap

LossP/E TTM



Cytek Biosciences Inc

4.620

+0.080+1.76%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cytek Biosciences Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cytek Biosciences Inc's Score

Industry at a Glance

Industry Ranking

63 / 209

Overall Ranking

149 / 4614

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.125

Target Price

+10.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cytek Biosciences Inc Highlights

StrengthsRisks

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.20% year-on-year.

Overvalued

The company’s latest PE is -44.99, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 76.25M shares, decreasing 13.72% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 438.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.77, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 52.29M, representing a year-over-year increase of 1.54%, while its net profit experienced a year-over-year increase of 682.15%.

Score

Industry at a Glance

Previous score

7.77

Change



Financials

9.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.15

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.22

Key Metrics

Free cash flow

No Data

Cytek Biosciences Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 8.56, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -44.99, which is -1663.30% below the recent high of 703.39 and -1565.49% above the recent low of -749.38.

Score

Industry at a Glance

Previous score

8.56

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 63/209

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.20, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Cytek Biosciences Inc is 4.25, with a high of 8.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.125

Target Price

+10.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Cytek Biosciences Inc

CTKB

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 8.52, which is higher than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 5.12 and the support level at 3.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.43

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.085

Buy

RSI(14)

67.814

Neutral

STOCH(KDJ)(9,3,3)

64.131

Buy

ATR(14)

0.250

High Vlolatility

CCI(14)

171.758

Buy

Williams %R

24.092

Buy

TRIX(12,20)

0.267

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.204

Buy

MA10

4.110

Buy

MA20

4.092

Buy

MA50

3.936

Buy

MA100

3.790

Buy

MA200

3.906

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 59.93%, representing a quarter-over-quarter decrease of 13.85%. The largest institutional shareholder is The Vanguard, holding a total of 7.74M shares, representing 6.08% of shares outstanding, with 32.77% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

15.38M

-6.80%

The Vanguard Group, Inc.

Star Investors

7.74M

-19.35%

HHLR Advisors, Ltd.

6.66M

Yan (Ming)

6.06M

+0.25%

Jiang (Wenbin)

5.31M

+1.00%

Topline Capital Management, LLC

5.23M

+255.68%

Brown Capital Management, LLC

7.11M

-4.74%

State Street Investment Management (US)

4.17M

-4.76%

Dimensional Fund Advisors, L.P.

3.45M

+21.06%

Geode Capital Management, L.L.C.

2.73M

+1.60%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.58, which is equal to the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.